The best-selling anti-epileptic drug, the Shanghai company's first review

Pharmaceutical Network July 23rd, July 20, the official website of the State Drug Administration shows that Shanghai Qingping Pharmaceutical Co., Sodium Valproate tablets through consistency evaluation, for the first in China-meter net data show that in 2019 China's public medical institutions terminal sodium valproate sales of 2.08 billion yuan, in the anti-epileptic drug TOP20 generic drugs, with 38.4% of the market share ranked firstsodium valproate is a nitrogen-free broad-spectrum anti-epileptic drug, can competitively inhibit Y-aminobutyric acid transaminase, improve the concentration of Y-aminobutyric acid to achieve anticonvulsive effect, all types of small seizures, muscle-array epilepsy, limited seizures, large seizures and mixed epilepsy are effective, clinically more used in other anti-epileptic drugs are ineffective with various epilepsy: 2015-2019 China's public medical institutions terminal sodium valproate sales (units: 10,000 yuan) are currently listed in the domestic market sodium valproate main dosage forms are injections, slow release tablets, ordinary tablets, syrups and oral solutionsIn recent years, sales of sodium valproate in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) have increased year by year, with sales of 2.08 billion yuan in 2019, up 9.39 percent year-on-year, according to data from-meter netranked first in the anti-epileptic drug TOP20 generic drug with a market share of 38.4%table: sodium valproate consistency evaluation report Note: with the data of the internal net that has been evaluated, there are currently 3 pharmaceutical companies to copy 3 categories submitted sodium valproate injection application, there is no enterprise approved; Class submitted sodium valproate oral liquid listing application, is still in the "in the review and approval (in the drug review center)," 3 pharmaceutical companies submitted sodium valproate tablet consistency evaluation supplement application, of which Shanghai Qingping Pharmaceutical Products has been successfully evaluated, the first in Chinaat present, Shanghai Qingping Pharmaceutical industry has 2 varieties submitted consistency evaluation supplementapplication application, sodium valproate tablets have been successfully evaluated, for the company's first over-evaluated varietiesSource: Minnet Database, Official Website of the State Drug Administration.